Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

BACKGROUND: Inhibition of programmed cell death receptor protein-1 (PD-1) has proven to be a highly effective strategy for immunotherapy of cancer. Approvals of both PD-1 and PD-L1 inhibitors [PD-(L)1i] in multiple tumor types are evidence of the durable benefits they provide to patients with cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulos, Kyriakos P., Lakhani, Nehal, Falchook, Gerald S., Riley, Gosia, Baeck, Johan, Brown, Karen S., Gordon, Gilad, Le, Lidya, Wang, Judy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907044/
https://www.ncbi.nlm.nih.gov/pubmed/32989552
http://dx.doi.org/10.1007/s00262-020-02730-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907044/
https://www.ncbi.nlm.nih.gov/pubmed/32989552
http://dx.doi.org/10.1007/s00262-020-02730-5

Ejemplares similares